GERN
Geron Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
1.52
▼ 0.03 (1.91%)
MARKET · —
Price
Open
1.56
Prev close
1.55
Day high
1.57
Day low
1.50
Volume
4.43M
Market cap
$976.56M
P/E (TTM)
—
52W range
1.04 – 2.01
Trailing performance
Returnvs SPY
1W
+3.40%
+4.8%
1M
+4.83%
+1.1%
3M
+20.63%
+17.5%
6M
-19.15%
-30.2%
YTD
+15.15%
+2.9%
1Y
+9.35%
-10.6%
3Y
-43.70%
-117.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$976.56M
Enterprise value$797.85M
Revenue (TTM)$204.56M
Gross profit$119.67M
EBITDA$-34.80M
Net income$-67.61M
EPS (TTM)$-0.11
Free cash flow$-78.37M
Total cash$300.85M
Total debt$122.14M
Book value / share$0.34
Shares outstanding642.47M
Float556.32M
Short % of float11.98%
Dividend yield—
Beta (5Y)0.59
Valuation & profitability ratios
Trailing P/E—
Forward P/E38.00
PEG ratio—
Price / sales—
Price / book4.47
EV / revenue3.90
EV / EBITDA-22.93
Gross margin58.50%
Operating margin-22.01%
Profit margin-33.05%
Return on equity-28.28%
Return on assets-4.11%
Debt / equity55.87
Current ratio6.92
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $183.88M | $76.99M | $237.00K | $596.00K |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$85.78M | -$174.57M | -$184.13M | -$141.90M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$85.78M | -$174.57M | -$184.13M | -$141.90M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.01 | -0.02 | -146.4% |
| Mar 2026 | -0.02 | -0.00 | +75.5% |
| Dec 2025 | -0.05 | -0.02 | +52.9% |
| Sep 2025 | -0.04 | -0.03 | +24.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.01 | 1 | $60.69M | +28.5% |
| Next quarter | 0.00 | 1 | $66.27M | +38.0% |
| Current year | -0.02 | 1 | $236.28M | +28.5% |
| Next year | 0.04 | 1 | $341.96M | +44.7% |
Analyst targets & ownership
Mean target$4.25
High target$6.00
Low target$3.00
Implied upside179.53%
Analyst count4
ConsensusBUY
Strong buy / Buy1 / 3
Hold1
Sell / Strong sell0 / 0
Held by insiders0.08%
Held by institutions76.57%
Institutions holding327
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
513.98K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | SPIEGEL ROBERT J Director |
STOCK | 6.10K | $7.81K | Direct |
| Mar 31, 26 | SPIEGEL ROBERT J Director |
STOCK | 5.24K | $7.81K | Direct |
| Feb 18, 26 | ROBERTSON MICHELLE Chief Financial Officer |
— | 27.50K | — | Direct |
| Feb 18, 26 | ROBERTSON MICHELLE Chief Financial Officer |
SELL | 9.86K | $19.12K | Direct |
| Dec 31, 25 | SPIEGEL ROBERT J Director |
STOCK | 5.92K | $7.81K | Direct |
| Sep 30, 25 | SPIEGEL ROBERT J Director |
STOCK | 5.70K | $7.81K | Direct |
| Jun 30, 25 | SPIEGEL ROBERT J Director |
STOCK | 5.54K | $7.81K | Direct |
| May 9, 25 | LAWLIS VIRGIL BRYAN JR. Director |
BUY | 13.30K | $15.67K | Direct |
| Mar 31, 25 | SPIEGEL ROBERT J Director |
STOCK | 4.91K | $7.81K | Direct |
| Feb 27, 25 | SCARLETT JOHN A Chief Executive Officer |
BUY | 12.50K | $22.06K | Direct |
| Feb 27, 25 | SAMUELS SCOTT ALAN Officer |
BUY | 15.00K | $24.15K | Direct |
| Feb 27, 25 | ZIEGLER JAMES Officer |
BUY | 100.00K | $160.00K | Direct |
| Dec 31, 24 | SPIEGEL ROBERT J Director |
STOCK | 2.21K | $0 | Direct |
| Dec 31, 24 | SPIEGEL ROBERT J Director |
STOCK | 2.21K | $7.81K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
LAWLIS VIRGIL BRYAN JR. |
Director | 13.30K | Purchase |
ROBERTSON MICHELLE |
Chief Financial Officer | 17.64K | Conversion of Exercise of derivative security |
SAMUELS SCOTT ALAN |
Officer | 26.68K | Purchase |
SCARLETT JOHN A |
Chief Executive Officer | 137.50K | Purchase |
SPIEGEL ROBERT J |
Director | 205.81K | Stock Award(Grant) |
ZIEGLER JAMES |
Officer | 100.00K | Purchase |
Moving averages & technicals
SMA 10
1.54
-1.34% from price
SMA 20
1.48
+2.46% from price
SMA 50
1.41
+7.73% from price
SMA 100
1.43
+6.37% from price
SMA 200
1.42
+7.15% from price
EMA 12
1.52
-0.12% from price
EMA 26
1.48
+2.52% from price
EMA 50
1.45
+5.18% from price
RSI (14)
52.9
Neutral
MACD (12,26,9)
0.04
Hist 0.00
ATR (14)
0.10
6.86% of price
Realised vol 30D
79.9%
Annualised
Bollinger upper
1.69
20, 2σ
Bollinger lower
1.28
20, 2σ
50 / 200 cross
Death
1.41 vs 1.42
Trend bias
Above 200
+7.15%
Risk profile
Beta vs SPY
1.28
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
79.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-43.6%
Peak to trough
Max drawdown 5Y
-79.0%
Peak to trough
ATR 14
0.10
6.86% of price
Beta (reported)
0.59
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.04
Call-heavy session
Put / call open interest
0.12
Positioning, not flow
Max pain
1.50
-1.3% from spot
ATM implied vol
99.2%
Nearest strike to spot
Skew (10% OTM)
-18.0%
Calls bid over puts
Call volume
407
Contracts, this expiry
Put volume
16
Contracts, this expiry
Heaviest call OI
2.00
1.61K contracts
Heaviest put OI
2.00
204 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 4d ago
Geron (GERN) Stock Looks Reasonable On Sales But Weak On Returns
Simply Wall St. · 12d ago
Geron (GERN) Back In Focus As Fresh Guidance And Earnings Test Its Undervalued Narrative
Simply Wall St. · 13d ago
Geron (GERN) Is Up 14.7% After Issuing First RYTELO Revenue Guide And Narrowing Losses - Has The Bull Case Changed?
Simply Wall St. · 13d ago
Geron (GERN) Q2 2026 Earnings Call Transcript
Motley Fool · 16d ago
Geron Corp (GERN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
GuruFocus.com · 17d ago
Geron Corporation Q2 2026 Earnings Call Summary
Moby · 17d ago
Geron Q2 Earnings Call Highlights
MarketBeat · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.